Related Experiment Video
Updated: Feb 14, 2026

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue NALT in Mouse Responses to Vaccines
Published on: August 1, 2012
Reduced QSOX1 enhances radioresistance in nasopharyngeal carcinoma
Lei Zhou1, Hong-Min Chen1, Song Qu1,2,3
1Department of Radiation Oncology, Affiliated Tumor Hospital of Guangxi Medical University and Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, P.R. China.
Abstract:
Radioresistance is a major cause leads to treatment failure in nasopharyngeal carcinoma (NPC). In our previous study, we identified that QSOX1 is a differentially expressed protein in NPC cell lines with variable radiosensitivities. The present study aimed to investigate the biological behavior of QSOX1 in nasopharyngeal carcinoma (NPC) and its effect on radiosensitivity. The levels of QSOX1 detected by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC) in radioresistant NPC patient sera and tissue samples were markedly lower than those in radiosensitive samples. Small hairpin RNAs (shRNAs) were employed to knock down endogenous QSOX1 expression in CNE-2 cells, and then, radiosensitivity, apoptosis, migration and invasion were assessed using colony formation, Cell Counting Kit-8 (CCK-8), flow cytometry, and transwell assays, respectively. Tumor growth and radioresistance were also evaluated using a xenograft model in nude mice. The shRNA-mediated knockdown of QSOX1 significantly increased cell survival under irradiation (IR) and weakened radiosensitivity, which was likely due to a reduction in the cell apoptosis rate after IR. Moreover, QSOX1 silencing led to the suppression of cellular migration and invasion. Similar results were obtained with the xenograft mouse model. Thus, targeting QSOX1 will provide a new avenue for increasing the sensitivity of NPC to radiotherapy.
Insights
Lower QSOX1 protein levels correlate with radioresistance in nasopharyngeal carcinoma (NPC). Suppressing QSOX1 in NPC cells reduces radiosensitivity, apoptosis, and metastasis, suggesting QSOX1 as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Nasopharyngeal carcinoma (NPC) treatment failure is often due to radioresistance.
- Previous work identified QSOX1 as differentially expressed in NPC cells with varying radiosensitivities.
Purpose of the Study:
- To investigate the biological role of QSOX1 in NPC.
- To determine QSOX1's impact on NPC radiosensitivity and treatment outcomes.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC) to quantify QSOX1 levels in patient samples.
- Small hairpin RNA (shRNA) to knockdown QSOX1 in CNE-2 NPC cells.
- In vitro assays (colony formation, CCK-8, flow cytometry, transwell) and in vivo xenograft models to assess radiosensitivity, apoptosis, migration, and invasion.
Main Results:
- Markedly lower QSOX1 levels were observed in radioresistant NPC patient sera and tissues compared to radiosensitive samples.
- Knockdown of QSOX1 significantly increased cell survival under irradiation, reducing radiosensitivity.
- QSOX1 silencing decreased apoptosis rates post-irradiation and suppressed cellular migration and invasion.
- Xenograft models confirmed QSOX1 knockdown's role in promoting tumor growth and radioresistance.
Conclusions:
- QSOX1 expression is inversely correlated with radiosensitivity in NPC.
- Targeting QSOX1 presents a potential strategy to enhance NPC radiosensitivity and improve radiotherapy efficacy.
Related Concept Videos
Suctioning the Nasopharyngeal Airway
Equipment Required
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Self-Evaluation: Self-Enhancement and Self-Verification
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Drug Permeability Enhancement

